Science

can-you-sanitize-the-inside-of-your-nose-to-prevent-covid?-nope,-fda-says.

Can you sanitize the inside of your nose to prevent COVID? Nope, FDA says.

COVID-19, fda, health, nasal spray, SARS-CoV-2, Science, warning letter / /

doesn’t pass the sniff test —

There are a lot of COVID nasal sprays for sale, but little data to show they work.

–

Can you sanitize the inside of your nose to prevent COVID? Nope, FDA says.

More than four years after SARS-CoV-2 made its global debut, the US Food and Drug Administration is still working to clear out the bogus and unproven products that flooded the market, claiming to prevent, treat, and cure COVID-19.

The latest example is an alcohol-based sanitizer meant to be smeared inside the nostrils. According to its maker, the rub can protect you from becoming infected with SARS-CoV-2 and other nasty germs, like MRSA, and that protection lasts up to 12 hours after each swabbing. That all sounds great, but according to the FDA, none of it is proven. In a warning letter released Tuesday, the agency determined the sanitizer, called Nozin, is an unapproved new drug and misbranded.

While ethyl alcohol is used in common topical antiseptics, like hand sanitizers, the FDA does not generally consider it safe for inside the nostrils—and the agency is unaware of any high-quality clinical data showing the Nozin is safe, let alone effective. The FDA also noted that, for general over-the-counter topical antiseptics, calling out specific pathogens it can fight off—like SARS-CoV-2 and MRSA—is not allowed under agency rules without further FDA review. Making claims about protection duration is also not allowed.

The FDA’s warning letter is nothing to sneeze at; the letter threatens seizure and injunction for failing to adequately respond.

Nozin’s maker, Maryland-based Global Life Technologies Corp., did not immediately respond to a request for comment from Ars. On its website, the company touts its product’s effectiveness with a link to a published study from 2014, indicating that use of Nozin lowered the colonization levels of S. aureus and other bacteria in the noses of 20 healthy health care workers. The study did not address protection from infection or carriage of any viruses. The company also lists unpublished studies indicating that the product can kill bacteria in laboratory conditions, does not irritate skin, and lowered bacterial growth in the noses of 30 people over a 12-hour period.

This is far from the first dubious, nasal-based COVID product the FDA has called out. There was the Corona-cure nasal spray of 2020, and the Halodine and the NanoBio Protect nasal antiseptics of 2021. That year, the Federal Trade Commission sued a company called Xlear over allegedly false claims that its nasal spray can prevent and treat COVID-19. At least two more nasal spray makers received FDA warning letters in 2022.

To date, the FDA has not approved any nasal sprays to prevent or treat COVID-19, and the scant data on their efficacy remains inconclusive. But there are still plenty of such products for sale online. Most, like Nozin, claim to work by killing bacteria and viruses directly. One product, a nitric oxide nasal spray called Sanotize, is currently in a Phase III clinical trial to test whether it can prevent SARS-CoV-2 infections. Others claim to work by coating the nasal passage with the gelling agent iota-carrageenan to provide a barrier to viral entry. A pilot clinical trial of 400 health care workers in Argentina published in 2021 found that the use of an iota-carrageenan nasal spray led to a 4 percent absolute risk reduction in SARS-CoV-2 infection.

Can you sanitize the inside of your nose to prevent COVID? Nope, FDA says. Read More »

google,-environmental-defense-fund-will-track-methane-emissions-from-space

Google, Environmental Defense Fund will track methane emissions from space

edf, Energy, Google, methane, Science, Sustainability / /

It’s a gas —

Satellite data + Google Maps + AI should help figure out where methane is leaking.

–

computer-generated image of a satellite highlighting emissions over a small square on the globe.

Enlarge / With color, high resolution.

Google/EDF

When discussing climate change, attention generally focuses on our soaring carbon dioxide emissions. But levels of methane have risen just as dramatically, and it’s a far more potent greenhouse gas. And, unlike carbon dioxide, it’s not the end result of a valuable process; methane largely ends up in the atmosphere as the result of waste, lost during extraction and distribution.

Getting these losses under control would be one of the easiest ways to slow down greenhouse warming. But tracking methane emissions often comes from lots of smaller, individual sources. To help get a handle on all the leaks, the Environmental Defense Fund has been working to put its own methane-monitoring satellite in orbit. On Wednesday, it announced that it was partnering with Google to take the data from the satellite, make it publicly available, and tie it to specific sources.

The case for MethaneSAT

Over the course of 20 years, methane is 84 times more potent than carbon dioxide when it comes to greenhouse warming. And most methane in the atmosphere ultimately reacts with oxygen, producing water vapor and carbon dioxide—both of which are also greenhouse gasses. Those numbers are offset by the fact that methane levels in the atmosphere are very low, currently just under two parts per million (versus over 400 ppm for CO2). Still, levels have gone up considerably since monitoring started.

The primary source of the excess methane is the extraction and distribution of natural gas. In the US, the EPA has developed rules meant to force companies with natural gas infrastructure to find and fix leaks. (Unsurprisingly, Texas plans to sue to block this rule.) But finding leaks has turned out to be a challenge. The US has been using industry-wide estimates that turned out to be much lower than numbers based on monitoring a subset of facilities.

Globally, that sort of detailed surveying simply isn’t possible, and we don’t have the type of satellite-based instruments we need to focus on methane emissions. A researcher behind one global survey said, “We were quite disappointed because we discovered that the sensitivity of our system was pretty low.” (The survey did identify sites that were “ultra emitters” despite the sensitivity issues.)

To help identify the major sources of methane release, the Environmental Defense Fund, a US-based NGO, has spun off a project called MethaneSAT that will monitor the emissions from space. The project is backed by large philanthropic donations and has partnered with the New Zealand Space Agency. The Rocket Lab launch company will build the satellite control center in New Zealand, while SpaceX will carry the 350 kg satellite to orbit in a shared launch, expected in early March.

Once in orbit, the hardware will use methane’s ability to absorb in the infrared—the same property that causes all the problems—to track emissions globally at a resolution down below a square kilometer.

Handling the data

That will generate large volumes of data that countries may struggle to interpret. That’s where the new Google partnership will come in. Google will use the same AI capability it has developed to map features such as roads and sidewalks on satellite images but repurpose it to identify oil and gas infrastructure. Both the MethaneSAT’s emissions data and infrastructure details will be combined and made available via the company’s Google Earth service.

Top image: A view of an area undergoing oil/gas extraction. Left: a close-up of an individual drilling site. Right: Computer-generated color coding of the hardware present at the site.

Top image: A view of an area undergoing oil/gas extraction. Left: a close-up of an individual drilling site. Right: Computer-generated color coding of the hardware present at the site.

Google / EDF

The project builds off work Google has done previously by placing methane monitoring hardware on Street View photography vehicles, also in collaboration with the Environmental Defense Fund.

In a press briefing, Google’s Yael Maguire said that the challenge is keeping things up to date, as infrastructure in the oil and gas industry can change fairly rapidly. While he didn’t use it as an example, one illustration of that challenge was the rapid development of liquified natural gas import infrastructure in Europe in the wake of Russia’s invasion of Ukraine.

The key question, however, is one of who’s going to use this information. Extraction companies could use it to identify the sites of leaks and fix them but are unlikely to do that in the absence of a regulatory requirement. Governments could rely on this information to take regulatory actions but will probably want some sort of independent vetting of the data before doing so. At the moment, all EDF is saying is that it’s engaging in discussions with several parties about potentially using the data.

One clear user will be the academic community, which is already using less-targeted satellite data to explore the issue of methane emissions.

Regardless, as everyone involved in the project emphasizes, getting methane under control is probably the easiest and quickest way to eliminate a bit of impending warming. And that could help countries meet emissions targets without immediately starting on some of the slower and more expensive options. So, even if no one has currently committed to using this data, they may ultimately come around—because using it to do something is better than doing nothing.

Google, Environmental Defense Fund will track methane emissions from space Read More »

scientists-found-a-stone-age-megastructure-submerged-in-the-baltic-sea

Scientists found a Stone Age megastructure submerged in the Baltic Sea

Archaeology, megastructures, Science, stone age / /

They built a wall —

“Blinkerwall” may have been a “desert kite,” used to channel and hunt reindeer.

–

Graphical reconstruction of a Stone Age wall as it may been used: as a hunting structure in a glacial landscape.

Enlarge / Graphical reconstruction of a Stone Age wall as it may been used: as a hunting structure in a glacial landscape.

Michał Grabowski

In 2021, Jacob Geersen, a geophysicist with the Leibniz Institute for Baltic Sea Research in the German port town of Warnemünde, took his students on a training exercise along the Baltic coast. They used a multibeam sonar system to map the seafloor about 6.2 miles (10 kilometers) offshore.  Analyzing the resulting images back in the lab, Geersen noticed a strange structure that did not seem like it would have occurred naturally.

Further investigation led to the conclusion that this was a manmade megastructure built some 11,000 years ago to channel reindeer herds as a hunting strategy. Dubbed the “Blinkerwall,” it’s quite possibly the oldest such megastructure yet discovered, according to a new paper published in the Proceedings of the National Academy of Sciences—although precisely dating these kinds of archaeological structures is notoriously challenging.

As previously reported, during the 1920s, aerial photographs revealed the presence of large kite-shaped stone wall mega-structures in deserts in Asia and the Middle East that most archaeologists believe were used to herd and trap wild animals. More than 6,000 of these “desert kites” have been identified as of 2018, although very few have been excavated. Last year, archaeologists found two stone engravings—one in Jordan, the other in Saudi Arabia—that they believe represent the oldest architectural plans for these desert kites.

However, these kinds of megastructures are almost unknown in Europe, according to Geersen et al., because they simply didn’t survive the ensuing millennia. But the Baltic Sea basins, which incorporate the Bay of Mecklenburg where Geersen made his momentous discovery, are known to harbor a dense population of submerged archaeological sites that are remarkably well-preserved—like the Blinkerwall.

Morphology of the southwest–northeast trending ridge that hosts the Blinkerwall and the adjacent mound.

Enlarge / Morphology of the southwest–northeast trending ridge that hosts the Blinkerwall and the adjacent mound.

J. Geersen et al., 2024

After they first spotted the underwater wall, Geeren enlisted several colleagues to lower a camera down to the structure. The images revealed a neat row of stones forming a wall under 1 meter (3.2 feet) in height. There are 10 large stones weighing several tons, spaced at intervals, and connected by more than 1,600 smaller stones (less than 100 kilograms or 220 pounds).  “Overall, the ten heaviest stones are all located within regions where the stonewall changes is strike direction,” the authors wrote. The length of the wall is 971 meters (a little over half a mile).

They concluded that the wall didn’t form through natural processes like a moving glacier or a tsunami, especially given the careful placement of the larger stones wherever the wall zigs or zags. It is more likely the structure is manmade and built over 10,000 years ago, although the lack of other archaeological evidence like stone tools or other artifacts makes dating the site difficult. They reasoned that before then, the region would have been covered in a sheet of ice. The immediate vicinity would have had plenty of stones laying about to build the Blinkerwall. Rising sea levels then submerged the structure until it was rediscovered in the 21st century. This would make the Blinkerwall among the oldest and largest Stone Age megastructures in Europe.

As for why the wall was built, Geeren et al. suggest that it was used as a desert kite similar to those found in Asia and the Middle East. There are usually two walls in a desert kite, forming a V shape, but the Blinkerwall happens to run along what was once a lake. Herding reindeer into the lake would have slowed the animals, making them easier to hunt. It’s also possible that there is a second wall hidden underneath the sediment on the seafloor. “When you chase the animals, they follow these structures, they don’t attempt to jump over them,” Geersen told The Guardian. “The idea would be to create an artificial bottleneck with a second wall or with the lake shore.”

3D model of a section of the Blinkerwall adjacent to the large boulder at the western end of the wall.

Enlarge / 3D model of a section of the Blinkerwall adjacent to the large boulder at the western end of the wall.

Philipp Hoy, Rostock University

A similar submerged stone-walled drive lane, known as “Drop 45,” is located in Lake Huron in the US; divers found various lithic artifacts around the drive lane, usually in circular spots that could have served as hunting blinds. The authors suggest that the larger blocks of the Blinkerwall could also have been hunting blinds, although further archaeological surveys will be needed to test this hypothesis.

“I think the case is well made for the wall as an artificial structure built to channel movements of migratory reindeer,” archaeologist Geoff Bailey of the University of York, who is not a co-author on the paper, told New Scientist. Vincent Gaffney of the University of Bradford concurred. “Such a find suggests that extensive prehistoric hunting landscapes may survive in a manner previously only seen in the Great Lakes,” he said. “This has very great implications for areas of the coastal shelves which were previously habitable.”

PNAS, 2024. DOI: 10.1073/pnas.2312008121 (About DOIs).

Scientists found a Stone Age megastructure submerged in the Baltic Sea Read More »

cdc-to-update-its-covid-isolation-guidance,-ditching-5-day-rule:-report

CDC to update its COVID isolation guidance, ditching 5-day rule: Report

CDC, COVID-19, COVID-19 vaccine, health, isolation, masks, Science / /

update —

The agency is reportedly moving from the fixed time to a symptom-based isolation period.

–

CDC to update its COVID isolation guidance, ditching 5-day rule: Report

The Centers for Disease Control and Prevention is preparing to update its COVID-19 isolation guidance, moving from a minimum five-day isolation period to one that is solely determined by symptoms, according to a report from The Washington Post.

Currently, CDC isolation guidance states that people who test positive for COVID-19 should stay home for at least five days, at which point people can end their isolation as long as their symptoms are improving and they have been fever-free for 24 hours.

According to three unnamed officials who spoke with the Post, the CDC will update its guidance to remove the five-day minimum, recommending more simply that people can end their isolation any time after being fever-free for 24 hours without the aid of medication, as long as any other remaining symptoms are mild and improving. The change, which is expected to be released in April, would be the first to loosen the guidance since the end of 2021.

In an email to Ars, a CDC spokesperson did not confirm or deny the report, saying only that, “There are no updates to COVID guidelines to announce at this time. We will continue to make decisions based on the best evidence and science to keep communities healthy and safe.”

The Post notes that the proposed update to the guidance matches updated guidance from California and Oregon, as well as other countries.

The officials who spoke with the outlet noted that the loosened guidelines reflect that most people in the US have developed some level of immunity to the pandemic coronavirus from prior infections and vaccinations.

A report earlier this month found that the 2023–2024 COVID-19 vaccine was about 54 percent effective at preventing symptomatic COVID-19 when compared against people who had not received the latest vaccine. However, the CDC estimates that only about 22 percent of adults have received the updated shot.

Currently, the CDC recommends that people wear a mask for 10 days after testing positive unless they have two negative tests 48 hours apart. The Post reported that it’s unclear if the CDC will update its mask recommendation.

CDC to update its COVID isolation guidance, ditching 5-day rule: Report Read More »

judge-tosses-big-pharma-suit-claiming-drug-price-negotiation-is-unconstitutional

Judge tosses Big Pharma suit claiming drug price negotiation is unconstitutional

Astrazeneca, drug pricing, health, medicare, Pharmaceutical industry, PhRMA, Science / /

tossed —

The judge ruled that the court lacks jurisdiction.

–

Stephen Ubl, president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), speaks during a Bloomberg Live discussion in Washington, DC, on Tuesday, Sept. 19, 2017.

Enlarge / Stephen Ubl, president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), speaks during a Bloomberg Live discussion in Washington, DC, on Tuesday, Sept. 19, 2017.

A federal judge in Texas dismissed a lawsuit Monday brought by a heavy-hitting pharmaceutical trade group, which argued that forcing drug makers to negotiate Medicare drug prices is unconstitutional.

The dismissal is a small win for the Biden administration, which is defending the price negotiations on multiple fronts. The lawsuit dismissed Monday is just one of nine from the pharmaceutical industry, all claiming in some way that the price negotiations laid out in the Inflation Reduction Act of 2022 are unconstitutional. The big pharmaceutical companies suing the government directly over the negotiations include Johnson & Johnson, Bristol Myers Squibb, Novo Nordisk, Merck, and AstraZeneca.

Last month, a federal judge in Delaware heard arguments from AstraZeneca’s lawyers, which reportedly went poorly. AstraZeneca argued that Medicare’s new power to negotiate drug prices violates the company’s rights under the Fifth Amendment’s due process clause. The forced negotiations deprive the company of “property rights in their drug products and their patent rights” without due process, AstraZeneca claimed. But Colm Connolly, chief judge of the US District Court of Delaware, was skeptical of how that could be the case, according to a Stat reporter who was present for the hearing. Connolly noted that AstraZeneca doesn’t have to sell drugs to Medicare. “You’re free to do what you want,” Connolly reportedly said. “You may not make as much money.”

At a later point, Connolly bluntly commented: “I don’t find their argument compelling.”

Though the plaintiffs in the now-dismissed Texas also made an argument based on the Fifth Amendment’s due process clause, the case didn’t make it that far. US District Judge David Ezra in Austin, Texas, dismissed the case brought by one of the case’s three plaintiffs, saying the court lacked jurisdiction. And, because that one plaintiff is the only one based in the Western District of Texas, where the lawsuit was filed, he dismissed the case completely.

The three plaintiffs in the case were PhRMA, a powerful drug industry trade group representing high-profile drug makers, including Pfizer, GSK, Eli Lilly, and Sanofi; the Global Colon Cancer Association (GCCA); and the Texas-based National Infusion Center Association (NICA). Lawyers for the Biden administration filed a motion to dismiss the case, arguing that NICA is not a proper plaintiff.

Ezra found that for NICA to bring constitutional claims against Medicare’s price negotiations in a court, it is first required under federal rules to bring those claims through an administrative review process under the Medicare Act or the Centers for Medicare and Medicaid Services. Without a prior administrative review, the court has no jurisdiction.

“The Court lacks jurisdiction over NICA’s claims because the claims here ‘arise under’ the Medicare Act and the claims do not fall under the exception carved out for when claims may completely avoid judicial or administrative review. Therefore, NICA’s claims are dismissed without prejudice,” Ezra wrote in his ruling.

And, with the one Texas-based plaintiff, NICA, knocked out of the case, the Western Texas district is now the “improper venue” for a case brought by the remaining two plaintiffs, PhRMA and GCCA.

Ezra noted that in such situations, a judge can transfer the case to a court that would be considered a proper venue. But Ezra declined, noting that neither the plaintiffs nor defendants suggested a proper venue. And, even if they did, it likely wouldn’t matter, Ezra reasoned, because PhRMA and GCCA also haven’t gone through an administrative review.

“[T]he same federal jurisdictional defect likely exists for PhRMA and GCCA, as nothing suggests that either party has presented its claims to the [Health] Secretary,” Ezra wrote.

Ezra dismissed the case “without prejudice,” meaning the claims could be refiled. A spokesperson for PhRMA told FiercePharma: “We are disappointed with the court’s decision, which does not address the merits of our lawsuit, and we are weighing our next legal steps.”

Meanwhile, the first round of Medicare drug price negotiations is underway. Earlier this month, the federal government sent out its opening offers in the price negotiation process for the first 10 drugs selected. The bargaining will continue through the coming months, with an ending deadline of August 1, 2024. The prices will go into effect at the beginning of 2026.

Judge tosses Big Pharma suit claiming drug price negotiation is unconstitutional Read More »

“very-sick”-pet-cat-gave-oregon-resident-case-of-bubonic-plague

“Very sick” pet cat gave Oregon resident case of bubonic plague

bubonic plague, cat, CDC, fleas, infection, infectious diseases, Oregon, plague, rodents, Science, yersinia pestis / /

Surprise plague —

The person’s cat was reportedly extremely ill and had a draining abscess.

–

A cat, but not the one with plague.

Enlarge / A cat, but not the one with plague.

An Oregon resident contracted bubonic plague from their “very sick” pet cat, marking the first time since 2015 that someone in the state has been stricken with the Black Death bacterium, according to local health officials.

Plague bacteria, Yersinia pestis, circulates cryptically in the US in various types of rodents and their fleas. It causes an average of seven human cases a year, with a range of 1 to 17, according to the Centers for Disease Control and Prevention. The cases tend to cluster in two regions, the CDC notes: a hotspot that spans northern New Mexico, northern Arizona, and southern Colorado, and another region spanning California, far western Nevada, and southern Oregon.

The new case in Oregon occurred in the central county of Deschutes. It was fortunately caught early before the infection developed into a more severe, systemic bloodstream infection (septicemic plague). However, according to a local official who spoke with NBC News, some doctors felt the person had developed a cough while being treated at the hospital. This could indicate progression toward pneumonic plague, a more life-threatening and more readily contagious variety of the plague that spreads via respiratory droplets. Nevertheless, the person’s case reportedly responded well to antibiotic treatment, and the person is recovering.

Health officials worked to prevent the spread of the disease. “All close contacts of the resident and their pet have been contacted and provided medication to prevent illness,” Richard Fawcett, Deschutes County Health Officer, said in a news release.

Fawcett told NBC News that the cat was “very sick” and had a draining abscess, indicating “a fairly substantial” infection. The person could have become infected by plague-infected fleas from the cat or by handling the sick cat or its bodily fluids directly. Symptoms usually develop two to eight days after exposure, when the infection occurs in the lymph nodes. Early symptoms include sudden onset of fever, nausea, weakness, chills, muscle aches, and/or visibly swollen lymph nodes called buboes. If left untreated, the infection progresses to the septicemic or pneumonic forms.

It’s unclear how or why the cat became infected. But cats are particularly susceptible to plague and are considered a common source of infection in the US. The animals, when left to roam outdoors, can pick up infections from fleas as well as killing and eating infected rodents. Though dogs can also pick up the infection from fleas or other animals, they are less likely to develop clinical illness, according to the CDC.

While plague cases are generally rare in the US, Deschutes County Health Services offered general tips to keep from contracting the deadly bacteria, namely: Avoid contact with fleas and rodents, particularly sick, injured, or dead ones; Keep pets on a leash and protected with flea control products; Work to keep rodents out and away from homes and other buildings; and avoid areas with lots of rodents while camping and hiking and wear insect repellant when outdoors to ward off fleas.

According to the CDC, there were 496 plague cases in the US between 1970 and 2020. And between 2000 and 2020, the CDC counted 14 deaths.

“Very sick” pet cat gave Oregon resident case of bubonic plague Read More »

building-durable-basketball-players-from-the-ground-up-(way-up)

Building durable basketball players from the ground up (way up)

Science / /

he got game (and a good stretching regimen) —

Can new scientific insights help the newest crop of NBA stars stay healthy?

–

Victor Wembanyama of the San Antonio Spurs drives on Moritz Wagner of the Orlando Magic

Enlarge / Victor Wembanyama of the San Antonio Spurs drives on Moritz Wagner of the Orlando Magic during a game on February 8 in Orlando, Florida.

The NBA’s tallest rookie is 7 feet 4 inches tall with an 8-foot wingspan, but last year, a series of video clips highlighted his surprisingly nimble, and often shoeless, feet. In one clip, he’s pressing knees and ankles together while wiggling his toes and hopping forward. In another, he’s bear crawling along the baseline. And in yet another, his right heel and left toes are gliding in opposite directions, gym music pounding in the background, as he eases into the splits.

Victor Wembanyama (pronounced wem-ben-YAH-muh), was selected first in last June’s NBA draft at the age of 19. By then, he had played four years of professional basketball in his native France. With a preternatural blend of size, athleticism, and skill, Wembanyama is routinely described as a generational talent. And if the toe-exercise videos are any indication, his trainers appear determined to protect that talent: Sports medicine experts say that long limbs and feet—Wembanyama’s shoe size is 20.5—confer potential physical vulnerabilities.

Leg, arm, and foot bones all function like levers, and the longer they are, the more force is needed to stabilize them. Tall athletes may find it harder to control their movement as they land from a jump or quickly shift direction. Seven-footers, of course, aren’t the only athletes who get hurt while playing. Across the NBA, injuries are on the rise, with knee, ankle, and foot problems leading the way. Anecdotally, physicians and trainers also report seeing children, some as young as 10 years old, with severe sports-related injuries and chronic wear-and-tear that was once seen mainly in adults.

All of this has fueled a small but growing body of scientific research into basketball and other sports-related injuries. In biomechanics laboratories, experts are creating detailed assessments of how players move on the court. Epidemiologists are poring over reams of data. And NBA teams have been experimenting with new approaches for player safety, including an emphasis on load management, which seeks to optimize an athlete’s ratio of stress to rest.

Much of this science is still unsettled, and there is no foolproof method for injury prevention. But experts who spoke with Undark said there is a solid evidence base for specific warm-up programs, stretches, and exercises that reduce injuries. The findings have not been fully disseminated and implemented. Yet, there’s clearly interest in the topic.

The shoes of Victor Wembanyama, size 20.5, before a game in January. Across the NBA, injuries are on the rise, with knee, ankle, and foot problems leading the way. And experts say long limbs and feet confer potential physical vulnerabilities.

Enlarge / The shoes of Victor Wembanyama, size 20.5, before a game in January. Across the NBA, injuries are on the rise, with knee, ankle, and foot problems leading the way. And experts say long limbs and feet confer potential physical vulnerabilities.

Wembanyama’s barefoot calisthenics have inspired explanatory videos with titles like “Victor Wembanyama’s Weird Toe Workout EXPLAINED!” as well as comments and replies asserting that such exercises could have benefitted previous generations of tall players. “This is smart they’re trying to keep his feet healthy,” wrote a New York Knicks superfan on X, formerly known as Twitter. “[Too] many big men have gone down with foot injuries.”

Danny Seidman, a Michigan-based sports medicine physician (and self-described NBA fanatic), said he’s glad the videos went viral. They got people talking about injury prevention, which has come a long way over the past few decades. “It’s sad for me to see previous athletes in their 50s and 60s who are limping around or hunched over,” said Seidman. “We think we can avoid those sorts of things now.”

Building durable basketball players from the ground up (way up) Read More »

fake-grass,-real-injuries?-dissecting-the-nfl’s-artificial-turf-debate

Fake grass, real injuries? Dissecting the NFL’s artificial turf debate

american football, astroturf, Features, Football, nfl, Science, sports injuries, Super Bowl, super bowl lviii / /
Fake grass, real injuries? Dissecting the NFL’s artificial turf debate

iStock/Getty Images

Super Bowl LVIII will be played on a natural grass field in an indoor stadium in Las Vegas on February 11, 2024. How do you keep a grass field vibrant in such a hostile growing environment like the Nevada desert?

The answer: You don’t. By the end of the regular NFL season, paint was used to camouflage the reality that only a few scant patches of grass remained in Allegiant Stadium, home to the Las Vegas Raiders. Immediately after the Raiders’ last game on January 7, 2024, the field crew ripped up the remaining grass, installed California-grown sod over three days, and began the tedious process of keeping the grass alive long enough for the big game.

Herculean efforts to prepare a vibrant natural grass field for 2024’s Super Bowl LVIII are especially questionable when one realizes that Allegiant Stadium also has an artificial turf playing surface available (used by UNLV Football). Why don’t teams in hostile environments switch to more robust artificial turf, which is designed to overcome the many limitations of natural grass fields?

The answer lies in a debate over the safety of synthetic playing surfaces. While artificial turf manufacturers tout research that their products result in fewer injuries, the NFL Players Association (NFLPA) claims it raises injury risk and is advocating for its use to be abolished in the NFL. Let’s explore some key arguments of this debate, which continues to grab headlines with each high-profile NFL injury.

Super Bowl gridirons

Pressure for NFL field managers is especially high following the embarrassingly poor field conditions of last year’s Super Bowl. Super Bowl LVII took place at State Farm Stadium in Glendale, Arizona—another natural grass field in the desert (with a retractable roof, closed at night to protect the grass). Despite two years of preparation and an $800,000 investment, the grass field was a disaster, as players struggled to find footing on its slippery surface.

Veteran NFL groundskeeper George Toma attributed the mess to woefully improper field preparation. Players also complained about the slipping issue the previous time the Super Bowl was hosted at the natural grass field in State Farm Stadium eight years prior for Super Bowl XLIX in 2015. That year, the poor traction was blamed on the green paint used on the grass.

For perspective, some of the best sports field managers in the nation oversee field preparations for the Super Bowl. However, maintaining natural grass in desert conditions is so unfavorable (especially when the grass is sometimes indoors) that even the best can mess it up.

None of these issues existed when the Super Bowl was last played on artificial turf. Super Bowl LVI in 2022 was held at SoFi Stadium in Inglewood, California, home to both the Los Angeles Rams and Chargers. Not only did the artificial turf stand up to double the workload during the regular season (hosting home games for the LA Rams and the LA Chargers), but it also withstood a busy playoff season. The artificial turf field at SoFi Stadium hosted NFL games through the regular season and right up to the last playoff game when the LA Rams beat the San Francisco 49ers. Two weeks later, the Rams ended up winning Super Bowl LVI on the very same surface.

While turf avoids the durability issues seen with grass surfaces, players have widespread concerns about its safety—a recent poll by the NFLPA reported 92 percent of players favored grass.

Fake grass, real injuries? Dissecting the NFL’s artificial turf debate Read More »

alternate-qubit-design-does-error-correction-in-hardware

Alternate qubit design does error correction in hardware

Computer science, photons, Physics, quantum computing, quantum mechanics, Science / /

We can fix that —

Early-stage technology has the potential to cut qubits needed for useful computers.

–

Image of a complicated set of wires and cables hooked up to copper colored metal hardware.

Nord Quantique

There’s a general consensus that performing any sort of complex algorithm on quantum hardware will have to wait for the arrival of error-corrected qubits. Individual qubits are too error-prone to be trusted for complex calculations, so quantum information will need to be distributed across multiple qubits, allowing monitoring for errors and intervention when they occur.

But most ways of making these “logical qubits” needed for error correction require anywhere from dozens to over a hundred individual hardware qubits. This means we’ll need anywhere from tens of thousands to millions of hardware qubits to do calculations. Existing hardware has only cleared the 1,000-qubit mark within the last month, so that future appears to be several years off at best.

But on Thursday, a company called Nord Quantique announced that it had demonstrated error correction using a single qubit with a distinct hardware design. While this has the potential to greatly reduce the number of hardware qubits needed for useful error correction, the demonstration involved a single qubit—the company doesn’t even expect to demonstrate operations on pairs of qubits until later this year.

Meet the bosonic qubit

The technology underlying this work is termed a bosonic qubit, and they’re not anything new; an optical instrument company even has a product listing for them that notes their potential for use in error correction. But while the concepts behind using them in this manner were well established, demonstrations were lagging. Nord Quantique has now posted a paper in the arXiv that details a demonstration of them actually lowering error rates.

The devices are structured much like a transmon, the form of qubit favored by tech heavyweights like IBM and Google. There, the quantum information is stored in a loop of superconducting wire and is controlled by what’s called a microwave resonator—a small bit of material where microwave photons will reflect back and forth for a while before being lost.

A bosonic qubit turns that situation on its head. In this hardware, the quantum information is held in the photons, while the superconducting wire and resonator control the system. These are both hooked up to a coaxial cavity (think of a structure that, while microscopic, looks a bit like the end of a cable connector).

Massively simplified, the quantum information is stored in the manner in which the photons in the cavity interact. The state of the photons can be monitored by the linked resonator/superconducting wire. If something appears to be off, the resonator/superconducting wire allows interventions to be made to restore the original state. Additional qubits are not needed. “A very simple and basic idea behind quantum error correction is redundancy,” co-founder and CTO Julien Camirand Lemyre told Ars. “One thing about resonators and oscillators in superconducting circuits is that you can put a lot of photons inside the resonators. And for us, the redundancy comes from there.”

This process doesn’t correct all possible errors, so it doesn’t eliminate the need for logical qubits made from multiple underlying hardware qubits. In theory, though, you can catch the two most common forms of errors that qubits are prone to (bit flips and changes in phase).

In the arXiv preprint, the team at Nord Quantique demonstrated that the system works. Using a single qubit and simply measuring whether it holds onto its original state, the error correction system can reduce problems by 14 percent. Unfortunately, overall fidelity is also low, starting at about 85 percent, which is significantly below what’s seen in other systems that have been through years of development work. Some qubits have been demonstrated with a fidelity of over 99 percent.

Getting competitive

So there’s no question that Nord Quantique is well behind a number of the leaders in quantum computing that can perform (error-prone) calculations with dozens of qubits and have far lower error rates. Again, Nord Quantique’s work was done using a single qubit—and without doing any of the operations needed to perform a calculation.

Lemyre told Ars that while the company is small, it benefits from being a spin-out of the Institut Quantique at Canada’s Sherbrooke University, one of Canada’s leading quantum research centers. In addition to having access to the expertise there, Nord Quantique uses a fabrication facility at Sherbrooke to make its hardware.

Over the next year, the company expects to demonstrate that the error correction scheme can function while pairs of qubits are used to perform gate operations, the fundamental units of calculations. Another high priority is to combine this hardware-based error correction with more traditional logical qubit schemes, which would allow additional types of errors to be caught and corrected. This would involve operations with a dozen or more of these bosonic qubits at a time.

But the real challenge will be in the longer term. The company is counting on its hardware’s ability to handle error correction to reduce the number of qubits needed for useful calculations. But if its competitors can scale up the number of qubits fast enough while maintaining the control and error rates needed, that may not ultimately matter. Put differently, if Nord Quantique is still in the hundreds of qubit range by the time other companies are in the hundreds of thousands, its technology might not succeed even if it has some inherent advantages.

But that’s the fun part about the field as things stand: We don’t really know. A handful of very different technologies are already well into development and show some promise. And there are other sets that are still early in the development process but are thought to have a smoother path to scaling to useful numbers of qubits. All of them will have to scale to a minimum of tens of thousands of qubits while enabling the ability to perform quantum manipulations that were cutting-edge science just a few decades ago.

Looming in the background is the simple fact that we’ve never tried to scale anything like this to the extent that will be needed. Unforeseen technical hurdles might limit progress at some point in the future.

Despite all this, there are people backing each of these technologies who know far more about quantum mechanics than I ever will. It’s a fun time.

Alternate qubit design does error correction in hardware Read More »

rocket-report:-us-military-still-wants-point-to-point;-india’s-big-2024-ambitions

Rocket Report: US military still wants point-to-point; India’s big 2024 ambitions

rocket report, Science, Space / /
A Falcon 9 rocket launched NASA's PACE spacecraft this week.

Enlarge / A Falcon 9 rocket launched NASA’s PACE spacecraft this week.

SpaceX

Welcome to Edition 6.30 of the Rocket Report! Looking ahead, there are some interesting launches coming up in the middle of this month. Here are some we have our eyes on: Intuitive Machines’ lunar lander on a Falcon 9 and a re-flight of Japan’s big H3 rocket next week; then there’s an Electron launch of an intriguing Astroscale mission and NASA’s Crew-8 the following week. Good luck to all.

As always, we welcome reader submissions, and if you don’t want to miss an issue, please subscribe using the box below (the form will not appear on AMP-enabled versions of the site). Each report will include information on small-, medium-, and heavy-lift rockets as well as a quick look ahead at the next three launches on the calendar.

Was Transporter created to ‘kill’ small launch? SpaceX’s Transporter missions, which regularly fly 100 or more small satellites into low-Earth orbit on Falcon 9 rideshare missions, have unquestionably harmed small satellite launch companies. While companies like Rocket Lab or Virgin Orbit could offer smallsat operators a precise orbit, there was no way to compete on price. “The Transporter program was created a few years ago with, in my opinion, the sole purpose of trying to kill new entrants like us,” said Sandy Tirtey, director of global commercial launch services at Rocket Lab, during a panel at the SmallSat Symposium on Wednesday.

Low-price guarantee … The panel was covered by Space News, and the rest of the article includes a lot of comments from small launch providers about how they provide value with dedicated services and so forth—pretty typical fare. However, the story does not really explore Tirtley’s statement. So, was Transporter created to kill small launch companies? As someone who has reported a lot on SpaceX over the years, I’ll offer my two cents. I don’t think the program was created with this intent; rather, it filled a market need (only Electron and India’s PSLV were meeting commercial smallsat demand in any volume at the time). It also gave Falcon 9 more commercial missions. However, I do believe it was ultimately priced with the intent of cutting small launch off at the knees.

FAA investigating Virgin Galactic’s dropped pin. Virgin Galactic reported an anomaly on its most recent flight, Galactic 06, which took place two weeks ago from a spaceport in New Mexico. The company said it discovered a dropped pin during a post-flight review of the mission, which carried two pilots and four passengers to an altitude of 55.1 miles (88.7 km). This alignment pin, according to Virgin Galactic, helps ensure the VSS Unity spaceship is aligned to its carrier aircraft when mating the vehicles, Ars reports.

Corrective actions to be required … Virgin Galactic said it reported the anomaly to the Federal Aviation Administration (FAA) on January 31. On Tuesday, the FAA confirmed that there was no public property or injuries that resulted from the mishap. “The FAA is overseeing the Virgin Galactic-led mishap investigation to ensure the company complies with its FAA-approved mishap investigation plan and other regulatory requirements,” the federal agency said in a statement. Before VSS Unity can return to flight, the FAA must approve Virgin Galactic’s final report, including corrective actions to prevent a similar problem in the future. (submitted by Ken the Bin)

The easiest way to keep up with Eric Berger’s space reporting is to sign up for his newsletter, we’ll collect his stories in your inbox.

HyImpulse ships suborbital rocket to launch site. German launch startup HyImpulse has confirmed that its SR75 rocket and all related support systems have been boxed up and have embarked on the long journey to Australia, European Spaceflight reports. SR75 is a single-stage suborbital launch vehicle that is designed to be capable of delivering up to 250 kilograms to a maximum altitude of around 200 kilometers.

Testing a pathfinder … The debut flight of SR75 had initially been slated to occur from SaxaVord in the United Kingdom. In fact, HyImpulse had received approval for the flight from the UK Civil Aviation Authority in mid-2023. However, with financial issues forcing work on the site to be temporarily slowed, HyImpulse was forced to look elsewhere. The launch will now take place from the South Launch Koonibba Test Range in Australia, possibly as soon as March. The test will certify several critical elements of the company’s larger orbital SL1 rocket. (submitted by Ken the Bin)

Rocket Report: US military still wants point-to-point; India’s big 2024 ambitions Read More »

a-sleuthing-enthusiast-says-he-found-the-us-military’s-x-37b-spaceplane

A sleuthing enthusiast says he found the US military’s X-37B spaceplane

military space, Science, Space, spaceplane, US Space Force, X-37b / /

Found —

Officials didn’t disclose details about the X-37B’s orbit after its December launch.

–

File photo of an X-37B spaceplane.

Enlarge / File photo of an X-37B spaceplane.

Boeing

It turns out some of the informed speculation about the US military’s latest X-37B spaceplane mission was pretty much spot-on.

When the semi-classified winged spacecraft launched on December 28, it flew into orbit on top of a SpaceX Falcon Heavy rocket, which is much larger than the Atlas V and Falcon 9 rockets used to launch the X-37B on its previous missions.

This immediately sparked speculation that the X-37B would reach higher altitudes than its past flights, which remained in low-Earth orbit at altitudes of a few hundred miles. A discovery from Tomi Simola, a satellite tracking hobbyist living near Helsinki, Finland, appears to confirm this suspicion.

On Friday, Simola reported on social media and on SeeSat-L, a long-running online forum of satellite tracking enthusiasts, that he detected an unidentified object using a sky-watching camera. The camera is designed to continuously observe a portion of the sky to detect moving objects in space. A special software program helps identify known and unknown objects.

“Exciting news!” Simola posted on social media. “Orbital Test Vehicle 7 (OTV-7), which was launched to classified orbit last December, was seen by my SatCam! Here are images from the last two nights!”

Exciting news!

Orbital Test Vehicle 7 (OTV-7), which was launched to classified orbit last December, was seen by my SatCam!

Here are images from the last two nights! pic.twitter.com/3twOVdovVc

— Tomppa 🇺🇦 (@tomppa77) February 9, 2024

Mike McCants, one of the more experienced satellite observers and co-administrator of the SeeSat-L forum, agreed with Simola’s conclusion that he found the X-37B spaceplane.

“Congrats to Tomi Simola for locating the secret X-37B spaceplane,” posted Jonathan McDowell, an astrophysicist and widely respected expert in spaceflight activity.

Higher than ever

Amateur observations of the spaceplane indicate it is flying in a highly elliptical orbit ranging between 201 and 24,133 miles in altitude (323 and 38,838 kilometers). The orbit is inclined 59.1 degrees to the equator.

This is not far off the predictions from the hobbyist tracking community before the launch in December. At that time, enthusiasts used information about the Falcon Heavy’s launch trajectory and drop zones for the rocket’s core booster and upper stage to estimate the orbit it would reach with the X-37B spaceplane.

The Space Force has not released any information about the orbit of the X-37B. While it took hobbyists about six weeks to find the X-37B on this mission, it typically took less time for amateur trackers to locate it when it orbited at lower altitudes on its previous missions. Despite the secrecy, it’s difficult to imagine the US military’s adversaries in China and Russia didn’t already know where the spaceplane was flying.

Military officials usually don’t disclose details about the X-37B’s missions while they are in space, providing updates only before each launch and then after each landing.

This is the seventh flight of an X-3B spaceplane since the first one launched in 2010. In a statement before the launch in December, the Space Force said this flight of the X-37B is focused on “a wide range of test and experimentation objectives.” Flying in “new orbital regimes” is among the test objectives, military officials said.

The military has two Boeing-built X-37B spaceplanes, or Orbital Test Vehicles, in its inventory. They are reusable and designed to launch inside the payload fairing of a conventional rocket, spend multiple years in space with the use of solar power, and then return to Earth for a landing on a three-mile-long runway, either at Vandenberg Space Force Base in California or at NASA’s Kennedy Space Center in Florida.

It resembles a miniature version of NASA’s retired space shuttle orbiter, with wings, deployable landing gear, and black thermal protection tiles to shield its belly from the scorching heat of reentry. It measures 29 feet (about 9 meters) long, roughly a quarter of the length of NASA’s space shuttle, and it doesn’t carry astronauts.

The X-37B has a cargo bay inside the fuselage for payloads, with doors that open after launch and close before landing. There is also a service module mounted to the back end of the spaceplane to accommodate additional experiments, payloads, and small satellites that can deploy in orbit to perform their own missions.

All the Space Force has said about the payloads on the current X-37B flight is that its experiment package includes investigations into new “space domain awareness technologies.” NASA is flying an experiment on the X-37B to measure how plant seeds respond to sustained exposure to space radiation. The spaceplane’s orbit on this flight takes it through the Van Allen radiation belts.

The secrecy surrounding the X-37B has sparked much speculation about its purpose, some of which centers on ideas that the spaceplane is part of a classified weapons platform in orbit. More likely, analysts say, the X-37B is a testbed for new space technologies. The unusual elliptical orbit for this mission is similar to the orbit used for some of the Space Force’s satellites designed to detect and warn of ballistic missile launches.

McDowell said this could mean the X-37B is testing out an infrared sensor for future early warning satellites, but then he cautioned this would be “just a wild speculation.”

Speculation is about all we have to go on regarding the X-37B. But it seems we no longer need to speculate about where the X-37B is flying.

A sleuthing enthusiast says he found the US military’s X-37B spaceplane Read More »

big-pharma-spends-billions-more-on-executives-and-stockholders-than-on-r&d

Big Pharma spends billions more on executives and stockholders than on R&D

bernie sanders, Bristol-Myers Squibb, drug pricing, Johnson & Johnson, merck, patents, PBMs, Pharmaceutical industry, research and development, Science / /

Greed —

Senate report points to greed and “patent thickets” as key reasons for high prices.

–

Big Pharma spends billions more on executives and stockholders than on R&D

When big pharmaceutical companies are confronted over their exorbitant pricing of prescription drugs in the US, they often retreat to two well-worn arguments: One, that the high drug prices cover costs of researching and developing new drugs, a risky and expensive endeavor, and two, that middle managers—pharmacy benefit managers (PBMs), to be specific—are actually the ones price gouging Americans.

Both of these arguments faced substantial blows in a hearing Thursday held by the Senate Committee on Health, Education, Labor and Pensions, chaired by Sen. Bernie Sanders (I-Vt.). In fact, pharmaceutical companies are spending billions of dollars more on lavish executive compensation, dividends, and stock buyouts than they spend on research and development (R&D) for new drugs, Sanders pointed out. “In other words, these companies are spending more to enrich their own stockholders and CEOs than they are in finding new cures and new treatments,” he said.

And, while PBMs certainly contribute to America’s uniquely astronomical drug pricing, their profiteering accounts for a small fraction of the massive drug market, Sanders and an expert panelist noted. PBMs work as shadowy middle managers between drugmakers, insurers, and pharmacies, setting drug formularies and consumer prices, and negotiating rebates and discounts behind the scenes. Though PBMs practices contribute to overall costs, they pale compared to pharmaceutical profits.

Rather, the heart of the problem, according to a Senate report released earlier this week, is pharmaceutical greed, patent gaming that allows drug makers to stretch out monopolies, and powerful lobbying.

On Thursday, the Senate committee gathered the CEOs of three behemoth pharmaceutical companies to question them on the drug pricing practices: Robert Davis of Merck, Joaquin Duato of Johnson & Johnson, and Chris Boerner of Bristol Myers Squibb.

“We are aware of the many important lifesaving drugs that your companies have produced, and that’s extraordinarily important,” Sanders said before questioning the CEOs. “But, I think, as all of you know, those drugs mean nothing to anybody who cannot afford it.”

America’s uniquely high prices

Sanders called drug pricing in the US “outrageous,” noting that Americans spend by far the most for prescription drugs in the world. A report this month by the US Department of Health and Human Services found that in 2022, US prices across all brand-name and generic drugs were nearly three times as high as prices in 33 other wealthy countries. That means that for every dollar paid in other countries for prescription drugs, Americans paid $2.78. And that gap is widening over time.

Focusing on drugs from the three companies represented at the hearing (J&J, Merck, and Bristol Myers Squibb), the Senate report looked at how initial prices for new drugs entering the US market have skyrocketed over the past two decades. The analysis found that from 2004 to 2008, the median launch price of innovative prescription drugs sold by J&J, Merck, and Bristol Myers Squibb was over $14,000. But, over the past five years, the median launch price was over $238,000. Those numbers account for inflation.

The report focused on high-profit drugs from each of the drug makers. Merck’s Keytruda, a cancer drug, costs $191,000 a year in the US, but is just $91,000 in France and $44,000 in Japan. J&J’s HIV drug, Symtuza, is $56,000 in the US, but only $14,000 in Canada. And Bristol Myers Squibb’s Eliquis, used to prevent strokes, costs $7,100 in the US, but $760 in the UK and $900 in Canada.

Sanders asked Bristol Myers Squibb’s CEO Boerner if the company would “reduce the list price of Eliquis in the United States to the price that you charge in Canada, where you make a profit?” Boerner replied that “we can’t make that commitment primarily because the prices in these two countries have very different systems.”

The powerful pharmaceutical trade group PhRMA, published a blog post before the hearing saying that comparing US drug prices to prices in other countries “hurts patients.” The group argued that Americans have broader, faster access to drugs than people in other countries.

Big Pharma spends billions more on executives and stockholders than on R&D Read More »